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VietnamDespite effective infant immunization against pertussis, the disease continues to circulate due to waning
immunity. Booster vaccinations against pertussis beyond infancy are widely recommended. In Vietnam,
however, no recommendations for pertussis boosters beyond the second year of life exist. This open-
label, single-centre study was designed to assess the safety of a single booster dose of reduced-anti
gen-content-diphtheria-tetanus-acellular-pertussis vaccine (dTpa) in 300 healthy Vietnamese children
(mean age 7.9 years), who had completed primary vaccination against diphtheria, tetanus and pertussis.
Solicited symptoms were recorded for 4 days and unsolicited and serious adverse events (SAEs) for
31 days post-vaccination. Pain and fatigue were the most common solicited local and general symptoms
in 35.0% and 14.0% of children, respectively. Grade 3 swelling occurred in 3 children; no large injection
site reactions or SAEs were reported. The dTpa booster vaccine was well tolerated and this study supports
its administration in school age Vietnamese children.
 2016 GSK group of companies. Published by Elsevier Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Vaccination coverage rates for infants against pertussis have
increased over recent years, but the burden of disease remains high
in developing countries [1–3]. Despite receiving a complete pri-
mary and booster vaccination course with combined diphtheria,
tetanus and pertussis vaccines (DTP) within the first two years of
life, older children and adolescents can become susceptible to per-
tussis or act as reservoirs of infection to younger pre-vaccinated
siblings due to waning of immunity over time [1,3]. Therefore peri-
odic booster vaccinations against pertussis might be necessary
throughout life. In Vietnam, the current recommendation for per-
tussis vaccination comprises a three-dose primary vaccination
course within the first six months of life, given in combination asDTP, followed by a booster before the age of two years [4]. Without
further follow-up booster vaccinations, waning immunity against
pertussis results in increased likelihood of infection and babies
too young to be vaccinated will be at greater risk of contracting
the disease [5,6]. This situation could further escalate since pri-
mary vaccination uptake rates in Vietnam have recently dipped,
with a decline in vaccine coverage to 83% in 2012 compared with
estimated values >93% for the previous 5 years [7].
Booster doses of the full-strength diphtheria-tetanus-acellular
pertussis (DTPa) containing vaccines, used for primary vaccination,
have been associated with increased reactogenicity [8]. Reduced-
antigen-content dTpa vaccines have therefore been developed for
boosting older children, adolescents and adults [9–11]. A three per-
tussis component, reduced-antigen-dose dTpa vaccine (BoostrixTM)
manufactured by GSK Vaccines, Belgium was first licensed in
Germany in 1999 and its safety and immunogenicity have been
well established in children from the age of four years upwards
[12–14].
This study was undertaken to evaluate the safety and reacto-
genicity of a single booster dose of dTpa in older Vietnamese chil-
dren, to support the registration of the vaccine for use in children
from four years of age.
Fig. 1. Solicited local and general adverse events during the 4-day post-vaccination
follow-up period (Total Vaccinated Cohort). Footnote: GI, gastrointestinal; temp,
temperature.
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2.1. Study design and participants
This was an open-label, phase III, safety and reactogenicity
study conducted at a single centre in Vietnam between 22
February and 10 May 2014 (NCT01988857). Healthy children aged
6–10 years, who had completed routine DTP vaccination in early
childhood (according to local recommendations) and had not
received any DTP vaccination within the last two years, were
enrolled. Children with a previous history of diphtheria, tetanus
or pertussis disease, any history of anaphylactic reaction to vaccine
components, any immunosuppressive or congenital disease, and
children who were in care were excluded from the study.
2.2. Ethical considerations
The study was conducted in accordance with Good Clinical
Practice guidelines and the Declaration of Helsinki. The protocol
and associated documents were reviewed and approved by local
ethics committees. Written informed consent was obtained before
any study procedure could be undertaken.
2.3. Study vaccines
All children received a single dose of dTpa as an intramuscular
injection into the deltoid muscle of the non-dominant arm, using a
needle at least 2.54 cm length and 22–25 gauge. The vaccine was
supplied as a prefilled syringe (lot number: C37B117A). Each
0.5 ml dose contained 2 IU (International units) diphtheria toxoid;
20 IU tetanus toxoid; 8 lg pertussis toxoid, 8 lg filamentous
haemagglutinin and 2.5 lg pertactin with 0.5 mg aluminium salts.
2.4. Assessment of reactogenicity and safety
Solicited local reactions (pain, redness and swelling) and gen-
eral symptoms (fatigue, fever, headache and gastrointestinal [GI]
symptoms) were recorded on diary cards on the day of vaccination
and for three subsequent days (4-day follow-up). Unsolicited
adverse events (AEs) and serious adverse events (SAEs) were
recorded by children’s parents or legally acceptable representa-
tives for 31 days after booster vaccination, using diary cards which
were returned at the last visit. All AEs were proactively followed by
the investigator after the initial report.
Symptom intensity was graded on a 3-point scale. Grade 1
symptoms were defined as easily tolerated, and Grade 2 symptoms
as interfering with normal every-day activities. Grade 3 redness
and swelling were defined as having a surface diameter >50 mm,
and Grade 3 fever as axillary temperature >39.0 C. For all other
symptoms ‘‘Grade 3” was defined as preventing normal activities.
The causality of systemic adverse events was assessed by the
investigator; all local adverse events were considered as being
related to study vaccine.
Children with large injection site swellings (diameter >100 mm,
noticeable diffuse swelling or increase in arm circumference) were
evaluated as soon as possible by the investigator.
2.5. Statistical analyses
A sample size of approximately 300 study participants was
required for the analysis of safety according to Vietnamese regula-
tory requirements. The analyses to ascertain the percentage of chil-
dren reporting adverse events with 95% confidence intervals (CI)
were performed on all vaccinated study participants (Total Vacci-
nated Cohort; TVC).Analyses were performed using SAS software version 9.2 (SAS
Institute Inc., Cary, NC, United States) on Statistical Drug Develop-
ment software and StatXact-8.1.
3. Results
3.1. Study participants
302 children were screened of whom 300 received the dTpa
vaccine and completed the study; there were no protocol devia-
tions. The mean age (SD) of the enrolled children was 7.9 (±1.38)
years; 151 study participants were male and all were of South East
Asian ethnicity.
3.2. Safety and reactogenicity
Solicited local and general adverse events occurring during the
4-day follow-up post-vaccination period are shown in Fig. 1. Pain
was the most common solicited local symptom in 105 (35.0%) chil-
dren. Redness and swelling occurred in 55 (18.3%) and 40 (13.3%)
children, respectively. Grade 3 swelling occurred in only 3 children
(1.0%) and no large injection site swelling was reported. No local
symptom requiring medical attention was reported.
Fatigue was the most common general symptom in 42 (14.0%)
children. There was a single case of grade 3 fatigue, but no other
grade 3 general adverse events. Medical advice was required for
1 child, for whom fatigue, headache and fever, were reported.
Unsolicited AEs were reported in 19 (6.3%) children during the
31-day follow-up (Table 1). Pharyngitis was the most common
unsolicited symptom in 7 (2.3%) children. No SAEs were recorded
during the study.
4. Discussion
In this reactogenicity study, a booster dose of reduced-antigen
content dTpa vaccine was well tolerated in Vietnamese children;
the safety profile was consistent with previous studies undertaken
in Asian children in Thailand, India, China and Taiwan [15,16]. In a
study conducted in 60 healthy Taiwanese children aged 6–8 years,
Table 1
Percentage of children reporting unsolicited adverse events within the 31-day post-vaccination period (Total Vaccinated Cohort; N = 300).
Primary System Organ Class Preferred term n % 95% CI
At least one symptom 19 6.3 3.9–9.7
General disorders Pyrexia 2 0.7 0.1–2.4
Infections and infestations Bronchitis 2 0.7 0.1–2.4
Nasopharyngitis 2 0.7 0.1–2.4
Pharyngitis 7 2.3 0.9–4.7
Respiratory tract infection 3 1.0 0.2–2.9
Tonsillitis 1 0.3 0.0–1.8
Respiratory, thoracic and mediastinal disorders Cough 3 1.0 0.2–2.9
Rhinorrhoea 1 0.3 0.0–1.8
Skin and subcutaneous tissue disorders Pruritus allergic 1 0.3 0.0–1.8
Footnote: N, total number of participants; n, number of participants in a given category; CI, confidence interval.
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reported with a higher incidence than in the current study. Pain
was also the most frequently reported local symptom (in 66.7%
of children) within the 15-day period following vaccination [16].
Redness and swelling occurred in 35% and 40% of children. Local
symptoms seemed to be approximately 3 times more frequent
than general symptoms, an observation which was not apparent
during our study. Incidence of fatigue (14.0% vs 16.7%), gastroin-
testinal symptoms (5.0% vs 6.7%) and headache (11.0% vs 10.0%)
were comparable between the present study and the one con-
ducted in Taiwanese children. A potential limitation of this com-
parison is that symptoms were reported over a longer period in
the Taiwanese trial. However, the majority of solicited symptoms
had an onset within 48 hours after vaccination. In general, consis-
tent patterns of AEs were described in a very broad range of age
groups following administration of a dTpa booster dose [17], and
no notable exceptions were observed in the present study.
A review of data on dTpa administered as a single booster dose
showed that although lower incidences of local and general soli-
cited reactions were reported following vaccination with dTpa
compared with DTPa, no significant differences between the vacci-
nes in terms of reactogenicity in children aged 4–8 years were evi-
dent [18]. However, repeated booster vaccination with full
strength DTPa (4th and 5th doses in toddlers and pre-school age
children, respectively) has been associated with large injection site
reactions [8]. The reduced-antigen content dTpa vaccine has been
previously shown to induce fewer extensive swelling reactions
than full-strength DTPa [19] and in this study, no large injection
site reactions were observed.
Using a booster dose beyond infancy is a prophylactic strategy
to prevent pertussis in older children and also to minimize the risk
of transmission to infants too young to be vaccinated, in whom the
disease is most severe [1]. Although this study was not designed to
evaluate immunogenicity, many previous studies from around the
world have demonstrated high immunogenicity in a similar aged
population [12,13,15,16,20] as well as in adolescents and adults
[17].
This was a reactogenicity study, limited in being open-label and
conducted at a single centre. In addition, no detailed information
on previous DTP vaccination (full or reduced doses) was collected,
which might impact the interpretation of the study results. A
strength of the study was that all 300 vaccinated children were fol-
lowed for the duration of the study; there were no withdrawals or
protocol violations.
In Vietnam, the current recommendation is for a three-dose pri-
mary vaccination series against diphtheria, tetanus and pertussis
within the first six months of age followed by a booster dose at
18 months of age [4]. Our results, which evaluated the safety and
reactogenicity of the vaccine are consistent with previous resultsand support the use of dTpa booster vaccination in school age Viet-
namese children.
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